The CIN framework assigns Vext Science a Neutral rating at 48/100, with conviction of 1 out of 5. The composite is a fixed blend of four pillars — fundamentals at 35 percent, regulatory at 25, market at 25, and editorial at 15 — and each contribution is inspectable. The strongest contribution comes from the fundamentals pillar at 60, and pulls the composite into the middle of the band. Editorial lags at 30, softening what would otherwise be a stronger reading.
Under the hood, the data points sit as follows: reported revenue growth of 5.2 percent year over year, an operating margin of 0.0 percent. Each of those figures ties back to a specific input in the pillar breakdown. Every input flowing into the pillar table comes from primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, filtered through CIN newsroom density. The 336-ticker CIN universe is scored deterministically, so Vext Science can be compared against the US operator peer set on identical inputs, refreshed on the ingest cycle.
The clearest catalyst is the next quarterly print. Fundamentals contribute 60 of the composite, and either an acceleration in top-line growth or a stabilization of the operating margin would move the score higher; a deterioration on either would compress it.
Bullish and Bearish Analyst Opinions for Vext Science (VEXTF)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Vext Science (VEXTF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
Bullish and bearish analyst opinions for Vext Science (VEXTF)
Bullish view. Vext Science is a tightly-run Arizona-anchored MSO with recent expansion into Ohio's adult-use market; bulls model EBITDA growth as Ohio ramps and the balance sheet stays disciplined relative to Tier-2 MSO peers.
Bearish view. Bears cite concentration in Arizona (a saturated market), the OTC listing that limits institutional participation, and the small-cap capital-access disadvantage relative to Tier-1 MSOs.
5-year weekly price history, intraday quotes, and 52-week range for VEXTF are maintained by Cannabis Investor News and refreshed throughout the trading day.